MINK THERAPEUTICS INC

NASDAQ: INKT (MiNK Therapeutics, Inc.)

Kemas kini terakhir: 2 hari lalu, 4:44PM

8.02

-0.59 (-6.85%)

Penutupan Terdahulu 8.61
Jumlah Dagangan 18,935
Purata Dagangan (3B) 15,631
Modal Pasaran 41,171,836
Harga / Jualan (P/S) 218.69
Julat 52 Minggu
7.76 (-3%) — 16.93 (111%)
Tarikh Pendapatan 11 Nov 2026
Margin Operasi (TTM) -5,720.70%
EPS Cair (TTM) -2.23
Nisbah Semasa (MRQ) 0.970
Aliran Tunai Operasi (OCF TTM) -7.16 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -6.21 M
Pulangan Atas Aset (ROA TTM) -61.63%

AISkor Stockmoo

-2.9
Keuntungan lemah. Kecairan jangka pendek nipis. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Pulangan atas Modal info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga telah jatuh jauh di bawah purata itu. Dagangan lebih tinggi pada hari harga turun. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini kebanyakannya positif. info
Sentimen Pegangan info NA
Institusi bersih -0.08% daripada saham dalam pemfailan 13F terkini: 7 pemegang menambah, 10 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -15.2% dari 31 Aug hingga 30 Oct 2026, 4.3 hari untuk tutup (FINRA). info
Aktiviti Orang Dalam info NA
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Perolehan sesaham meningkat setiap tahun. Mencatat kerugian dalam tahun-tahun kebelakangan. info
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Tiada isyarat jelas daripada sokongan dan rintangan. info
Skor Akhir -2.89
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok MiNK Therapeutics, Inc. Bercampur Bercampur

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
INKT 41 M - - - -2.9
PBLS 3 B - - 3.38 0.8
LEGN 3 B - - 2.59 -1.6
PVLA 2 B - - 10.82 0.9
MAZE 2 B - - 4.13 0.9
IMCR 1 B - - 3.24 -0.2

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 59.34%
% Dimiliki oleh Institusi 3.79%

Pemilikan

Nama Tarikh Syer Dipegang
Longbow Finance Sa 30 Sep 2026 16,667
Paladin Partners, Llc 30 Sep 2026 500
Covestor Ltd 30 Sep 2026 119

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 5.11%

Kedudukan Pemegang Saham
Bertambah 7 42,714
Berkurang 10 31,208
Baharu 1 72
Dijual habis 4 15,468

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 55,094 4.3
15 Oct 2026 47,778 2.4
30 Sep 2026 49,583 3.1
15 Sep 2026 57,136 3.1
31 Aug 2026 64,965 6.8
14 Aug 2026 78,320 9.0

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

6 Positif 0 Negatif 1 Neutral
Tarikh Jenis Butiran
11 Nov 2026 Yahoo Finance MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
First revenue lands as the ARDS trial enters randomized Phase II.
11 Nov 2026 Yahoo Finance MiNK Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of MiNK Therapeutics, Inc.'s Q3 2026 earnings call…
11 Nov 2026 Yahoo Finance MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
MiNK Therapeutics Inc (INKT) pairs durable oncology survival data with a newly initiated randomized ARDS program, all while maintaining a disciplined cash runway of at least 12 months.
11 Nov 2026 Yahoo Finance What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
MiNK Therapeutics (NASDAQ:INKT) has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with preliminary findings expected in the second half of 2026, executives said on the company’s first-quarter ear…
11 Nov 2026 Yahoo Finance MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates
MiNK Therapeutics, Inc. (INKT) delivered earnings and revenue surprises of +24.24% and +33.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
11 Nov 2026 Yahoo Finance MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue Selected as the cell therapy for the Draper-led team in ARPA-H’s BoSS program (up to $87 million in program wide funding) to move living…
06 Nov 2026 Yahoo Finance MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, reinforcing the rationale for an ongoing Phase 2 combination studySenolytic activity: agenT-797 and…
02 Nov 2026 Yahoo Finance MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual MeetingNEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE)…
02 Oct 2026 Yahoo Finance MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW…
30 Sep 2026 Yahoo Finance MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand…

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga telah jatuh jauh di bawah purata itu. Dagangan lebih tinggi pada hari harga turun.
Rintangan terdekat: 8.30 – 8.66 · paras sederhana

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda